Group 1 - The article reports on share buybacks conducted by various companies on December 18, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 1.055 million shares for a total of 636 million yuan, representing 1.030% of its total share capital for the year [2] - Other notable companies involved in the buyback include Xiaomi Group, which repurchased 3.75 million shares for 151 million yuan, and China National Petroleum Corporation, which repurchased 254,000 shares for 116.38 million yuan [3] Group 2 - The total number of shares repurchased by companies varied significantly, with China National Petroleum Corporation having a cumulative buyback of 230 million shares, which is 0.190% of its total share capital [3] - Companies like IGG and VITASOY also participated, with IGG repurchasing 182,000 shares for 68.49 million yuan and VITASOY repurchasing 122,000 shares for 77.94 million yuan [3] - The buyback activity reflects a strategic move by these companies to enhance shareholder value and manage their capital structure effectively [1][2]

Group 1 - On December 18, 60 Hong Kong-listed companies conducted share buybacks, totaling 49.5262 million shares and an aggregate amount of HKD 1.122 billion [1][2] - Tencent Holdings repurchased 1.055 million shares for HKD 636.47 million, with a year-to-date total buyback amount of HKD 75.587 billion [1][2] - Xiaomi Group-W repurchased 3.75 million shares for HKD 151.06 million, with a year-to-date total buyback amount of HKD 5.388 billion [1][2] - China COSCO Shipping Holdings repurchased 5.90 million shares for HKD 80.5574 million, with a year-to-date total buyback amount of HKD 6.615 billion [1][2] Group 2 - The highest buyback amount on December 18 was from Tencent Holdings at HKD 636.47 million, followed by Xiaomi Group-W at HKD 151.06 million [1][2] - The largest number of shares repurchased on December 18 was by Anton Oilfield Services, with a buyback of 11.936 million shares [1][2] - Other notable buybacks in terms of share quantity included China COSCO Shipping Holdings and Xiaomi Group-W, with 5.90 million and 3.75 million shares repurchased, respectively [1][2]

Core Insights - The collagen market is experiencing significant changes with new product approvals from Chongshan Bio and Aibai Rui, expanding the range of certified products in the industry [1][3] - The competition in the animal-derived collagen segment is intensifying, with companies focusing on differentiation through high concentration and specific indications [3] - The recombinant collagen sector is expected to outpace animal-derived collagen in growth, driven by safety and scalability advantages [6][9] Group 1: Product Approvals and Market Dynamics - Chongshan Bio's new product is the world's first implant with a concentration of 45mg/ml, aiming to establish a competitive edge through high concentration [3] - Aibai Rui's product targets specific needs for improving facial smoothness, attempting to create a niche in the crowded market [3] - The number of certified collagen products in China has increased to 14, indicating a growing market but also heightened competition [8] Group 2: Competitive Landscape - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading due to their early market entry and established clinical safety [3] - New entrants are seeking differentiation through quality ingredients and innovative product forms, such as Fiman Bio's focus on safety and convenience [3][9] - The recombinant collagen market is projected to grow at a compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, compared to 27.7% for animal-derived collagen [6] Group 3: Industry Trends and Future Outlook - The rise of recombinant collagen is attributed to its technological advantages, which mitigate risks associated with animal-derived products [6] - Companies are increasingly focusing on upstream raw material preparation and core production technologies to enhance product quality and safety [9] - The market is expected to see a surge in collagen product offerings in the next two years, as more companies enter the recombinant collagen space [8][9]

Core Viewpoint - The company, Giant Bio, has been actively repurchasing its shares on the Hong Kong Stock Exchange, indicating a strategy to support its stock price amid recent declines [1] Share Buyback Summary - On December 18, 2025, the company repurchased 400,000 shares at a price range of HKD 34.420 to HKD 35.040, totaling HKD 13.883 million [1] - The stock closed at HKD 34.580 on the same day, reflecting a decrease of 1.48%, with a total trading volume of HKD 179 million [1] - Since December 9, 2025, the company has conducted share buybacks for eight consecutive days, acquiring a total of 3.2 million shares for a cumulative amount of HKD 112 million [1] - During this buyback period, the stock has experienced a total decline of 5.00% [1] Buyback Details - The detailed buyback activities are as follows: - December 18: 40,000 shares at a maximum price of HKD 35.040 and a minimum price of HKD 34.420, amounting to HKD 1.3883 million [1] - December 17: 40,000 shares at a maximum price of HKD 35.220 and a minimum price of HKD 34.620, amounting to HKD 1.3971 million [1] - December 16: 40,000 shares at a maximum price of HKD 35.400 and a minimum price of HKD 34.680, amounting to HKD 1.4026 million [1] - December 15: 40,000 shares at a maximum price of HKD 35.240 and a minimum price of HKD 34.440, amounting to HKD 1.3917 million [1] - December 12: 40,000 shares at a maximum price of HKD 35.220 and a minimum price of HKD 35.000, amounting to HKD 1.4036 million [1] - December 11: 40,000 shares at a maximum price of HKD 35.360 and a minimum price of HKD 34.200, amounting to HKD 1.3888 million [1] - December 10: 40,000 shares at a maximum price of HKD 36.220 and a minimum price of HKD 35.620, amounting to HKD 1.4382 million [1] - December 9: 40,000 shares at a maximum price of HKD 36.180 and a minimum price of HKD 35.720, amounting to HKD 1.4376 million [1]

Group 1 - The company, Giant Bio (02367.HK), announced a share buyback on December 18, spending HKD 13.883 million to repurchase 400,000 shares [1]

Group 1 - The company, 巨子生物 (02367), announced a share buyback plan on December 18, 2025, involving an expenditure of HKD 13.883 million to repurchase 400,000 shares [1]

Group 1 - The company, Giant Bio (02367), announced a share buyback plan, intending to repurchase 400,000 shares at a cost of HKD 13.883 million [1]

表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | ...

Core Viewpoint - The collagen market is undergoing significant changes with the approval of new products from Chongshan Bio and Aibai Rui, expanding the competitive landscape in the animal-derived collagen sector. The focus is shifting towards differentiation in terms of cost-effectiveness, brand recognition, product safety, and efficacy as the market becomes increasingly crowded [1][2]. Group 1: New Product Approvals - Chongshan Bio's new product is the world's first collagen implant with a concentration of 45mg/ml, aiming to establish a strong product image through high concentration [2]. - Aibai Rui's new product targets specific needs by improving cheek smoothness, attempting to create a niche in the market despite similarities to existing products [4]. Group 2: Market Dynamics - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading the market due to their early entry and established brand recognition [6]. - New entrants are focusing on differentiation strategies, such as high-quality ingredients and innovative product forms, to compete effectively [6]. Group 3: Growth of Recombinant Collagen - The recombinant collagen market is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, surpassing the 27.7% CAGR of animal-derived collagen [8]. - The market size for recombinant collagen products in 2023 is estimated at 28.63 billion yuan, slightly below the 29.79 billion yuan for animal-derived collagen, indicating a shift in consumer preference towards recombinant options [8]. Group 4: Competitive Landscape and Future Outlook - The approval of new recombinant collagen products is intensifying competition, with companies like Jinjian Bio and others entering the market, challenging the previous dominance of Jinbo Bio [9]. - The future of the collagen market will likely see increased competition, with a focus on cost-effectiveness, brand strength, and product efficacy becoming critical for success [12].

12月18日，受美股科技股集体下挫影响，港股今日维持低位震荡走势，截止收盘，恒生指数涨0.12%报 25498.13点，恒生科技指数跌0.73%报5418.29点，国企指数跌0.02%报8841.51点，红筹指数跌0.26%报 4049.62点。 盘面上，大型科技股走势分化，阿里巴巴跌1.3%，京东集团跌0.09%，小米集团跌2.47%，网易涨 0.67%，美团涨0.1%，快手涨0.23%，哔哩哔哩涨0.26%；航空股延续涨势，东方航空涨超7%；煤炭股 午后走强，汇力资源涨超9%；锂电池股跌幅居前，宁德时代跌超3%；新消费概念股走弱，名创优品跌 超3%；其他股票中，舜宇光学科技跌超1%；曹操出行跌超12%，恒大物业跌超9%，中国中免跌超 5%；上海复旦涨超7%，招金矿业涨超6%。 企业新闻 远大医药(00512.HK)：自主研发的重磅全球创新放射性核素偶联药物 GPN01530 在美国获批开展临床研 究。 和谐汽车(03836.HK)：附属iCar Group Limited可能通过引入新投资者开展进一步股权融资，涉资4000万 美元。 中国中车(01766.HK)：集团及下属企业近三个月合计签订约533.1 ...